Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermaprazole is a topical formulation of esomeprazole, a proton pump inhibitor (PPI), that has been reformulated into a cream for dermatological applications. It appears to be under clinical investigation for the treatment of radiation dermatitis, particularly in cancer patients undergoing radiation therapy. The search results indicate that dermaprazole works through antioxidant, anti-inflammatory, and antifibrotic properties. It has shown efficacy in mitigating radiation-induced dermatitis in preclinical models by reducing inflammation and scarring. The mechanism involves early induction of endogenous antioxidant defense mechanisms and downregulation of pro-inflammatory and profibrotic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermaprazole.